The Effect of Huashibaidu Granule on Community-acquired Pneumonia in Children
Community-acquired Pneumonia
About this trial
This is an interventional health services research trial for Community-acquired Pneumonia focused on measuring Pediatric, community-acquired pneumonia, Huashibaidu granule
Eligibility Criteria
Inclusion Criteria: Han nationality. Diagnosed as community-associated pneumonia in children according to "Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version)". The first dose was given < 5 days from the onset of pneumonia (onset time is defined as the time of the first symptoms or signs of lower respiratory tract infection). The guardian agrees to participate in the study and signs the informed consent form. Exclusion Criteria: The subject has severe respiratory distress, cyanosis, consciousness disorder, refusal to eat or dehydration. The subject has chronic respiratory diseases, airway malformations, congenital heart disease, immune system diseases and other serious underlying diseases other than asthma. The subject has moderate to severe persistent asthma or is in the acute asthma exacerbation. The subject with influenza virus, pertussis, tuberculosis, fungi, and parasitic infections. The subject with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 1.5 times higher than normal values in blood biochemical detection items, abnormal renal function, or troponin. The subject with any other reason that investigators consider unsuitable to participate in this study.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Huashibaidu
Placebo
During the study, subjects diagnosed as community-acquired pneumonia in children according to "Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version)" will be assigned to the Huashibaidu group and the placebo group. Then they will receive 5 days treatment, prescribed by investigator according to study design. At the same time, they will finish a series of examinations, including biomarkers associated with infection, screening of pathogen, imaging examination and tNGS.
During the study, subjects diagnosed as community-acquired pneumonia in children according to "Guideline for diagnosis and treatment of community-acquired pneumonia in Children (2019 version)" will be assigned to the Huashibaidu group and the placebo group. Then they will receive 5 days treatment, prescribed by investigator according to study design. At the same time, they will finish a series of examinations, including biomarkers associated with infection, screening of pathogen, imaging examination and tNGS.